Comment Reply

Here are some more resources for you:

Sometimes it helps to have the exact terminology correct that the researchers are using regarding the current research for long-term use of letrozole: "extended adjuvant endocrine therapy for breast cancer" (for this one particular study).

Here are all of the researchers and their affiliations (initials are in parenthesis, please verify as I copied and pasted and could have made an error). They may know of other ongoing research and/or clinical trials, also. Please note: the authors listed are usually listed in a hierarchical order (and may be easier to contact someone further down the list??):

- Judith-Anne W. Chapman: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY)
- Daniel Meng: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY)
- Wendy Parulekar: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY)
- James N. Ingle: Department of Oncology, Mayo Clinic, Rochester, MN (JNI)
- Hyman B. Muss: Department of Medicine, Vermont Cancer Center, Burlington, VT (HBM)
- Lois Shepherd: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY)
- Michael Palmer: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY)
- Changhong Yu: National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, ON, Canada (JAWC, DM, LS, WP, MP, CY)
- Paul E. Goss: Department of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA (PEG)